New Approach to Cancer: Anti-Angiogenic Treatment in Vitro Lung Cancer

Objective: Angiogenesis is physiological event which involve endothelial cells and in malignant conditions involve bone-marrow derived cells, stromal cells related to tumor microenvironment is a multifactorial event. The main factor in this action is vascular endothelial growth factor (VEGFA). In recent years, bevacizumab (anti-VEGF) agent has been used against VEGFA receptor to block potential vascular signal in tumor cells and different activities were determined by in vitro experiments in lung cancer (NSCLC), colorectal cancer, breast cancer and renal cell carcinoma. The main objective of this study was to determine the vascularity and mechanism of vascular cancer in Bevacizumab-treated lung cancer cells compared to normal cells. Methods: Study of cell functions with main stimulant VEGF and Bevacizumab applications which provide angiogenesis blockade. Normal epithelial HUVEC line and lung cancer A549 cell line were used and cultured according to ATCC protocol. After application of different doses of agents, cell viability, Sytox proliferation index and Notch pathway activity responsible for angiogenesis were investigated. Results: Cells treated with VEGF showed a significant increase in cell viability with incubation for 24 hours. VEGF effect was significantly different in two cell lines compared to viability. In the application of Bevacizumab, the proliferation index of A549 cells decreased significantly and the ADAM10 protein level associated with the Notch mechanism was found to increase significantly compared to HUVEC cell. Conclusion: According to the findings, it is seen that it needs more detailed studies to explain the molecular mechanism of angiogenesis. In addition to conventional cancer treatment methods, enhancing combined therapies with known antiangiogenic agents will increase the chances of success.